Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ACTRN12625000863437) titled 'A first-in-human study evaluating the safety of AXA-042 in combination with an anti-PD-1 monoclonal antibody (cemiplimab) in patients with advanced solid tumors' on Aug. 8.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety
Primary Sponsor: Axelia Oncology Pty Ltd
Condition:
Advanced solid tumours
Advanced solid tumours
Cancer - Any cancer
Intervention:
The study will evaluate ascending doses of AXA-042 in combination with cemiplimab to investigate the safety, tolerability, pharma...